We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Let's try something different

6 March 2009 By Robert Cyran

After going hostile, the Swiss group has reversed tack and is making soothing sounds. By raising its bid to $93 a share, Roche has a chance to seal its deal before Genentech unveils drug data in April and possibly raises the purchase price.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)